In the Region
Capsule inhaler tested by Glaxo
GlaxoSmithKline P.L.C. is testing a capsule-based inhaler, suggesting the United Kingdom's biggest drugmaker is exploring a cheaper version of its best-selling asthma therapy for emerging markets or to compete with generic versions. Glaxo, which has about 5,000 employees in the Philadelphia area, completed a 60-patient, midstage trial in June comparing its Advair Diskus dry-powder inhaler with the capsule-based version of the drug-device combination, according to a posting on the clinicaltrials.gov website. The patent for Advair will expire in Europe next year. - Bloomberg News